Analyser av Q-Linea

Q-linea: Some take-aways from the Belgian tender win - Redeye

ASTar was awarded the tender at Cliniques Universitaires Saint-Luc in Brussels.

Q-linea: A minimum of SEK 183m is committed is committed in the rights issue - Redeye

Nexttobe, existing investor Ulf Landegren, certain board members, senior executives and guarantee commitments add up to SEK 183m out of SEK ...

Redeye • 09 Jan 09:36

Q-linea: Commits to a rights issue and improves the prospect pipeline - Redeye

Q-linea continues enhancing the pipeline of prospects, from entering tenders to close to the final contracts in Europe and the US.

Redeye • 06 Nov 2024 10:32

Q-linea: Committs to a rights issue of up to SEK 225m and improves its pipeline of prospects - Redeye

Q-linea continues improving the pipeline of prospects of various stages, from entering tenders to close to the final contracts in Europe and...

Redeye • 05 Nov 2024 11:18

Q-linea: Expands the European network of distributors - Redeye

Q-linea has signed S.C. Mecro System SRL as a distributor for Romania, which is part of an attractive region for Q-linea as Romania is one o...

Redeye • 11 Sep 2024 12:09

Q-linea: US progress - Redeye

The NTAP reimbursement decision is distinctly positive, and the CMS decision enables clinics to use the three-year NTAP reimbursement rate o...

Redeye • 30 Aug 2024 11:27

Q-linea Q2 Update: Commercial progress and financial challenges - Redeye

Q-linea and its distribution partners continue to advance pilot and tender process activities, which are leading indicators for future sales...

Redeye • 12 Jul 2024 08:28

Q-linea Q2: Reducing the OPEX base in a quarter where commercial progress are balanced by stretched liquidity - Redeye

Q-linea has reduced the OPEX by SEK 50m annually, suggesting a reduced OPEX run-rate to SEK 40-45m.

Redeye • 11 Jul 2024 08:23

Q-linea: ASTar is about to secure a 3-year US reimbursement at USD 97.50 - Redeye

CMS’ NTAP recommendation is positive, and we can expect a final decision by August, followed by a good chance that the NTAP reimbursement wi...

Redeye • 12 Jun 2024 10:50

Q-linea Update: Commercial progress and financial challenges - Redeye

Q-linea and its distribution partners continue to advance pilot and tender process activities, leading indicators for future sales.

Redeye • 04 Jun 2024 08:04

Q-linea Q1: Commercial progress together challenges to mitigate costs and secure growth capital - Redeye

Q-linea and its distribution partners continue to advance pilot and tender process activities, which is critical as this is paramount for fu...

Redeye • 31 May 2024 10:01

Q-linea: A US launch is in sight - Redeye

Q-linea has secured a US FDA approval, which is positive.

Redeye • 29 Apr 2024 09:29

Q-linea Q4 2023 update: Increasing commercial interest with a slow sales conversion - Redeye

Q-linea is making progress, including successful tenders, commercial evaluations, study support and partner discussions for the US market.

Redeye • 04 Mar 2024 10:04

Q-linea Q4 2023: Intensive period ahead of a momentous year - Redeye

Q-linea has finished 2023 and also started 2024 with plenty of action.

Redeye • 27 Feb 2024 09:34

Q-linea: A new SEK 50m OPEX reduction program - Redeye

Q-linea has announced a SEK 50m OPEX reduction ahead of the announced CEO change in 2024.

Redeye • 31 Jan 2024 07:25

Q-linea: Secures a public tender in Italy - Redeye

Q-linea wins a 5-year public tender with a total value of EUR 0.

Redeye • 16 Jan 2024 09:01

Q-linea: The first two US ASTar placements - Redeye

Q-linea finishes 2023 on a positive note as the company has placed the first two US ASTar systems.

Redeye • 29 Dec 2023 07:57

Q-linea November update: Progress ahead of commercial orders - Redeye

Q-linea is making progress, including commercial evaluations and partner discussions for the US market, and the Company are also confirming ...

Redeye • 06 Nov 2023 08:11

Q-linea: Progress ahead of commercial orders - Redeye

Q-linea is making progress, including commercial evaluations and partner discussions for the US market, and the Company are also confirming ...

Redeye • 02 Nov 2023 09:56

Q-linea: The Basingstoke study adds much needed commercial support - Redeye

The study presented as the first commercial evaluation of Q-linea's ASTar system in the UK (presented at the IBMS congress in Birmingham ear...

Redeye • 04 Oct 2023 08:38

Q-linea: Comment on the rights issue - Redeye

The outcome of the rights issue has been announced and it includes that approximately 74% have been subscribed with and without the support ...

Redeye • 25 Jul 2023 14:29

Q-linea: Building a launch platform - Redeye

Q-linea is in a transition period after the break with Thermo Fisher and in Q2 there are two delivered ASTar.

Redeye • 19 Jul 2023 07:37

Q-linea: Improved European distribution - Redeye

Q-linea continues to improve the network of European distribution partners and AST'ar is now represented in five European countries includin...

Redeye • 13 Jul 2023 10:04

Q-linea: A SEK 263m right issue - Redeye

A SEK 263m rights issue that is almost entirely covered without remuneration for the guarantee commitment nor the subscription undertakings.

Redeye • 02 Jun 2023 12:43

Q-linea is building a launch platform during 2023 - Redeye

Q-linea is in a transition period after the break with Thermo Fisher, and in Q1 there are no reported sales.

Redeye • 08 May 2023 12:57

Q-linea: Initial take on Q1 2023 - Redeye

Q-linea is in a transition period after the break with Thermo Fisher and in Q1 there is no reported sales.

Redeye • 04 May 2023 09:55

Q-linea: A targeted ASTar launch strategy - Redeye

Q-linea is in the early stage of its targeted European launch strategy.

Redeye • 23 Mar 2023 09:53

Q-linea: A targeted market approach with a doubled credit facility - Redeye

The go-to-market strategy is now implemented following the split with Thermo Fisher during the quarter.

Redeye • 16 Feb 2023 10:51

Q-linea: A new distribution partner for the UK market - Redeye

Q-linea has signed a new UK distribution partner in Canadian Pro-Lab Diagnostics.

Redeye • 09 Feb 2023 09:48

Q-Linea: Outlook after Q3 - Redeye

The Thermo Fisher divorce raise many questions and several remains after the Q3 update on the 31st October.

Redeye • 01 Nov 2022 09:25

Q-linea divorces from Thermo Fisher Scientific - Redeye

Q-linea and Thermo Fisher formed the collaboration in rearly February 2020.

Redeye • 27 Oct 2022 13:39

Q-linea: Q2 2022, progress with prospects and the US regulatory review - Redeye

In Q2, the first ASTar remains in the stage of expanding the lead prospect pipeline.

Redeye • 14 Jul 2022 10:07

Q-linea: US submission as ASTar approaches the largest market - Redeye

Q-linea and Thermo Fisher are already launching ASTar in Europe and the FDA 510 (k) submission opens up for a potential US approval within 6...

Redeye • 09 Jun 2022 15:33

Q-linea Q1 2022: Sales and commercial valuation progress - Redeye

Q-linea’s partner Thermo Fisher is launching ASTar in Europe.

Redeye • 05 May 2022 09:55

Q-linea Q4: Early launch feedback - Redeye

Q-linea's partner Thermo Fisher is launching ASTar in Europe, and Q4 is the first quarter featuring most of the launch (as of 7th of Octobe...

Redeye • 17 Feb 2022 09:33

Q-linea: Robust commercial evaluation feedback - Redeye

Q-linea's announcement regarding the commercial validation study together with the launch partner Therma Fisher is good news and well-timed ...

Redeye • 16 Feb 2022 11:28

Q-linea: Q2, ASTar ready to raise - Redeye

Q-linea's Q2 confirms that the ASTar launch is underway with initial sales and deliveries to the strategic global sales partner Thermo Fisch...

Redeye • 16 Jul 2021 09:13

Börskollen

För dig med koll på börsen